The multimodal approach for patients with peritoneal carcinomatosis involves what is known as cytoreductive surgery, followed by hyperthermic intraperitoneal chemotherapy (HIPEC).  The specifics of this treatment regimen and how it is performed is not something we typically discuss outside of service specific surgical oncology conferences.  To better prepare our residents and medical learners out there, today we sit down with our Chief Surgical Resident, Constantinos Zambirinis, MD to discuss the evolution, patient management, and future applications of HIPEC therapy.

Follow Dr Zambirinis on Twitter at: @czambir